Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Identification of fast and slow decliners in Alzheimer disease: a different approach.

Brooks JO 3rd, Yesavage JA.

Alzheimer Dis Assoc Disord. 1995;9 Suppl 1:S19-25. Review.

PMID:
7546595
2.

Is early-onset Alzheimer disease a distinct subgroup within the Alzheimer disease population?

Raskind MA, Carta A, Bravi D.

Alzheimer Dis Assoc Disord. 1995;9 Suppl 1:S2-6. Review.

PMID:
7546596
3.

Fast cognitive decline at the time of dementia diagnosis: a major prognostic factor for survival in the community.

Carcaillon L, Pérès K, Péré JJ, Helmer C, Orgogozo JM, Dartigues JF.

Dement Geriatr Cogn Disord. 2007;23(6):439-45. Epub 2007 Apr 26.

4.

A comment on age at onset as a subtype of Alzheimer disease.

Brooks JO 3rd.

Alzheimer Dis Assoc Disord. 1995;9 Suppl 1:S28-9. Review.

PMID:
7546598
5.

Identification of Alzheimer disease risk by functional magnetic resonance imaging.

Fleisher AS, Houston WS, Eyler LT, Frye S, Jenkins C, Thal LJ, Bondi MW.

Arch Neurol. 2005 Dec;62(12):1881-8.

PMID:
16344346
6.

A method for estimating progression rates in Alzheimer disease.

Doody RS, Massman P, Dunn JK.

Arch Neurol. 2001 Mar;58(3):449-54.

PMID:
11255449
7.

Age at onset and pattern of neuropsychological impairment in mild early-stage Alzheimer disease. A study of a community-based population.

Reid W, Broe G, Creasey H, Grayson D, McCusker E, Bennett H, Longley W, Sulway MR.

Arch Neurol. 1996 Oct;53(10):1056-61.

PMID:
8859068
8.

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.

Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, Clegg A.

Health Technol Assess. 2006 Jan;10(1):iii-iv, ix-xi, 1-160. Review.

9.

Molecular and cell biological aspects of Alzheimer disease.

Shastry BS.

J Hum Genet. 2001;46(11):609-18. Review.

PMID:
11721879
10.

Early-onset Alzheimer disease in families with late-onset Alzheimer disease: a potential important subtype of familial Alzheimer disease.

Brickell KL, Steinbart EJ, Rumbaugh M, Payami H, Schellenberg GD, Van Deerlin V, Yuan W, Bird TD.

Arch Neurol. 2006 Sep;63(9):1307-11.

PMID:
16966510
11.
12.

Overview of methodologic issues for pharmacologic trials in mild, moderate, and severe Alzheimer's disease.

Reisberg B, Franssen EH, Bobinski M, Auer S, Monteiro I, Boksay I, Wegiel J, Shulman E, Steinberg G, Souren LE, Kluger A, Torossian C, Sinaiko E, Wisniewski HM, Ferris SH.

Int Psychogeriatr. 1996 Summer;8(2):159-93. Review.

PMID:
8994889
13.

Clinical subtypes of Alzheimer's disease.

Petersen RC.

Dement Geriatr Cogn Disord. 1998;9 Suppl 3:16-24. Review.

PMID:
9853198
14.

Mild cognitive impairment: an opportunity to identify patients at high risk for progression to Alzheimer's disease.

Levey A, Lah J, Goldstein F, Steenland K, Bliwise D.

Clin Ther. 2006 Jul;28(7):991-1001. Review.

PMID:
16990077
15.

Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.

Higashida RT, Furlan AJ, Roberts H, Tomsick T, Connors B, Barr J, Dillon W, Warach S, Broderick J, Tilley B, Sacks D; Technology Assessment Committee of the American Society of Interventional and Therapeutic Neuroradiology; Technology Assessment Committee of the Society of Interventional Radiology.

Stroke. 2003 Aug;34(8):e109-37. Epub 2003 Jul 17. Erratum in: Stroke. 2003 Nov;34(11):2774.

16.

Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression.

Farlow MR, Hake A, Messina J, Hartman R, Veach J, Anand R.

Arch Neurol. 2001 Mar;58(3):417-22.

PMID:
11255445
17.

Neuropsychological prediction of conversion to Alzheimer disease in patients with mild cognitive impairment.

Tabert MH, Manly JJ, Liu X, Pelton GH, Rosenblum S, Jacobs M, Zamora D, Goodkind M, Bell K, Stern Y, Devanand DP.

Arch Gen Psychiatry. 2006 Aug;63(8):916-24.

PMID:
16894068
18.

Clinical applications of cognitive event-related potentials in Alzheimer's disease.

Olichney JM, Hillert DG.

Phys Med Rehabil Clin N Am. 2004 Feb;15(1):205-33. Review.

PMID:
15029906
19.

The methodology of studying decline in Alzheimer's disease.

Brooks JO 3rd, Kraemer HC, Tanke ED, Yesavage JA.

J Am Geriatr Soc. 1993 Jun;41(6):623-8.

PMID:
8505459
20.

Toward an early diagnosis and treatment of Alzheimer's disease.

Nordberg A.

Int Psychogeriatr. 2003 Sep;15(3):223-37.

PMID:
14756159
Items per page

Supplemental Content

Write to the Help Desk